0000950170-24-026782.txt : 20240305 0000950170-24-026782.hdr.sgml : 20240305 20240305211945 ACCESSION NUMBER: 0000950170-24-026782 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lyon Joseph Douglas CENTRAL INDEX KEY: 0001817838 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 24724125 MAIL ADDRESS: STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED STREET 2: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 ownership.xml 4 X0508 4 2024-03-01 0001088856 CORCEPT THERAPEUTICS INC CORT 0001817838 Lyon Joseph Douglas C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 false true false false Chief Accounting Officer false Common Stock 2024-03-01 4 F false 474 24.06 D 6300 D Common Stock 2024-03-01 4 A false 507 24.06 A 6807 D Common Stock 2024-03-01 4 A false 507 0.00 A 7314 D These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. Includes 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2024. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. /s/ Joseph Douglas Lyon 2024-03-05